Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

The growing risk of wildfires in the UK
As the UK goes through a cycle of heatwaves that are expected to become the ‘norm’ in the not too distant future , wildfires, often thought of as a pr
How to save on risk lines using analytics
Shield your organization both from unnecessary costs and insurance shortfalls. Risk analytics can help you drive optimized risk retention, insurance l
The continued outlook for the bulk purchase annuity market
The bulk purchase annuity (BPA) market has demonstrated remarkable resilience despite shifting economic conditions. Demand remains strong, but the con

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.